San Diego, USA-based biotech AnaptysBio’s (Nasdaq: ANAB) ground breaking Phase III trial results for imsidolimab, a novel inhibitor, bring renewed hope to patients battling generalized pustular psoriasis (GPP).
With a promising safety and tolerability profile, imsidolimab could potentially emerge as a vital treatment option for GPP, presenting a significant challenge to the current leader in the field, German family-owned pharma major Boehringer Ingelheim’s Spevigo (spesolimab-sbzo), according to sector analytics company GlobalData.
Reportedly, the trial revealed an impressive 53.3% success rate in achieving the primary endpoint, compared to 13.3% for the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze